Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.13) by 13.27 percent. This is a 21.6 percent increase over losses of $(1.25) per share from the same period last year.